FDA Approves Juvederm® Ultra XC for Use in Lips

Allergan has received FDA approval to market Juvederm® Ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. It is the only dermal filler that has proven results lasting up to one year for lip augmentation.

In clinical trials of Juvederm® Ultra XC, the majority of subjects reported improvement in the softness, smoothness and natural look and feel of their lips through one year. In clinical trials, 79% of subjects showed a meaningful improvement in lip fullness three months after treatment. Additionally, more than 78% of subjects reported an improvement in their overall satisfaction with the look and feel of their lips at one year after treatment.

"As the leader in medical aesthetics, Allergan is committed to continued research and development in this area," said Philippe Schaison, Executive Vice President & President, Allergan Medical. "Providing physicians and patients with premium products that allow them to achieve the aesthetic results they want is always our goal. Understanding that the desire with lip augmentation is to achieve a natural-looking and lasting result, we continued our research of Juvederm® Ultra XC for the lips. With this approval, Juvederm® Ultra XC is now the only filler that is approved to last up to one year in the lips while providing natural-looking results."

The Juvederm® collection of fillers are the number one selling dermal fillers in the US. More information about Juvederm® Ultra XC and the Juvederm® collection of fillers is available at www.Juvederm.com.